AzTrials
AzTrials

Inflammation Gastrointestinal TractNCT07591961

Identifying the Microbial Metabolome: The Missing Link Between Diet and Human Health

A study testing Food in people with Inflammation Gastrointestinal Tract, run by University of Aberdeen.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There is a lot of evidence to suggest that the bacteria in our gut play a major role in maintaining our health, but very little is known about the way in which this is achieved. In this study we will identify how the bacteria in out gut change the food we eat into products that may be responsible for this effect. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Inflammation Gastrointestinal Tract
What is being tested?
Food
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
No sites listed yet
Study dates
23 May 2016to 4 Sep 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • healthy male or females
  • aged between 18 and 55 years
  • able to give informed consent.

Who cannot join

  • are taking any medicines prescribed by their GP
  • are taking drugs to lower high cholesterol levels or high blood pressure
  • regularly take analgesics, antipyretic or anti-inflammatories
  • regularly take nutritional supplements
  • have taken antibiotics in the last three months
  • have given a large blood donation in last three months

About this study

Official title: Identifying Microbial Metabolites and the Bacteria Responsible for Their Formation

There is a lot of evidence to suggest that the bacteria in our gut play a major role in maintaining our health, but very little is known about the way in which this is achieved. In this study we will identify how the bacteria in out gut change the food we eat into products that may be responsible for this effect. We will also identify which bacteria are responsible for these changes. The foods we will look at are those suggested by the American Institute of Cancer Research to help prevent cancer; leafy green vegetables (cabbage, spinach), soft fruits (strawberry) cereal (oats) and plant-based protein (soya and pea). We will feed a diet rich in these foods to volunteers, monitoring the changes to the bacteria in our gut and the products produced. We will identify which products have potential to prevent cancer and also to work out how they are being produced. This work will provide new and important information that will allow us to understand more about the link between diet and health.

Read the detailed description

An accumulation of evidence indicates that the gut microbiota plays a vital role in inflammation and in the development of many diseases including diabetes, cardiovascular disease and cancer (Vijay-Kumar et al; 2010, Masklowski et al; 2009, Clarke et al 2010). Despite tremendous advances in the molecular approaches describing the composition of the human gut microbiota (Qin et al; 2012), to date relatively little is known about the functionality and role of even the most dominant commensal organisms within the human host. It is widely accepted that the products of microbial metabolism influence human health and disease, particularly regarding inflammation and immune responses. Despite this, many of the products of microbial metabolism of dietary compounds remain uncharacterised and consequently, their mechanisms of action unknown. As an enormous investment is being made to continue to characterise the microbiome and its interaction with the human immune system, there is now a critical requirement that the functional role of the microbiota is established. It is important that in addition to describing the microbial populations, the species are also defined by their function and metabolic outputs. This topic is exceptionally timely as there is increasing pressure to provide healthy food to a growing and increasingly unhealthy and aging population. Elucidating the products of microbial metabolism provides an essential and missing link between well-defined dietary intakes and the physiological effect of dietary constituents. Without this information, the nutritional value of food cannot be fully established, food claims effectively evaluated, nor the contribution of the gut microbiota to an overall aim of developing sustainable agricultural products beneficial for human health ascertained.

Diet, is a major factor shaping the composition of the colonic microbial community as well as a principal determinant of the gut metabolome. This is likely to explain why it is also a contributing factor in disease development and progression. Two related dietary factors appear to play a significant role in maintaining the equilibrium between health and disease. Firstly, the balance between different types of carbohydrate and protein is fundamental. Dietary fibre intake is strongly correlated with prevention of carcinogenesis and evidence that high protein-low carbohydrate diets are detrimental to health is increasing. Secondly, there is a large amount of literature suggesting that plant secondary metabolites have anti-cancer properties. In particular, almost all plant foods considered to have cancer-preventative properties are rich in non-nutrient compounds derived from the phenylpropanoid pathway. Much of the evidence for this however is obtained from in vitro data and there is very little evidence from both pre-clinical and human interventions to support their bioavailability and role in carcinogenesis. Data regarding the metabolism and bioavailability of phytochemicals is lacking, particularly with reference to transformation by the gut microbiota and absorption from the colon via the hepatic circulation. Additionally, the relationship between the main macronutrients (carbohydrate and protein) and non-nutrient phytochemicals is poorly understood. It is likely that it is a combination of these dietary factors that modulates both the gut bacteria and the overall metabolite profile, both in the gut and in the systemic circulation. This unique proposal will address the combined effects of the macro- and non-nutrient components of the diet, along with the gut microbial composition on the production of microbial metabolites.

Study Objectives

Specific objectives of the project are to:

  • Fully characterise dietary substrates in terms of their macro-, micro- and non-nutrient phytochemicals, providing the basis for detailed in vitro work and rigorous human intervention studies.
  • Identify the microbial metabolites which exhibit inflammatory activity at relevant in vivo concentrations. This will provide essential information, not currently available and will inform wider studies looking at the action of microbial metabolites on particular receptors and biomarkers of health.
  • Determine the functionality of the bacterial species responsible in terms of metabolite production. In this context, this will also identify the extent of redundancy of certain species.
  • Establish the role of major macronutrients in driving microbial metabolism, both in the production of phytochemical metabolites and the provision of carbohydrate and protein by-products.

Hypothesis Phytochemicals bound to plant polymers reach the colon largely intact and are metabolised and released by the gut microbiota where they can exert a direct anti-inflammatory action on the gut mucosa. Additionally mucosal uptake of these metabolites will suppress low-level chronic systemic inflammation. Furthermore, the source and type of polymer may improve or exacerbate the effect.

Being tested
Food
Keywords
Microbiome, Metabolome, Dietary Metabolites, Macronutrient Balance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FoodDietary supplement

    The intervention products will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period, in addition to the prescribed low-phytochemical diet.

Study groups in NCT07591961
Study groupRoleWhat they receive
oatActive comparatorThe intervention products will be commercially available oat provided as freeze dried powders baked into a bun.
Receives: Dietary Supplement: Food
peaActive comparatorThe intervention products will be commercially available pea provided as freeze dried powders baked into a bun.
Receives: Dietary Supplement: Food
soyaActive comparatorThe intervention products will be commercially available soya provided as freeze dried powders baked into a bun.
Receives: Dietary Supplement: Food
strawberryActive comparatorThe intervention products will be commercially available strawberry provided as freeze dried powders. The product will be consumed as bread rolls, each containing 33.3 g of the intervention product. Three rolls will be consumed per day during the five day intervention period
Receives: Dietary Supplement: Food
spinachActive comparatorThe intervention products will be commercially available spinach provided as freeze dried powders baked into a bun.
Receives: Dietary Supplement: Food
kaleActive comparatorThe intervention products will be commercially available kale provided as freeze dried powders baked into a bun.
Receives: Dietary Supplement: Food

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gut Microbial Metabolites

    Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine

    Measured: At Day 3

  2. Gut Microbial Metabolites

    Wide range of beneficial and detrimental microbial metabolites in faeces, blood and urine

    Measured: At Day 5

Secondary outcomes (2)
  1. Gut Microbial Species

    Bacteria

    Wide range of gut bacteria present in faecal samples

    Measured: At Day 3

  2. Gut Microbial Species

    Bacteria

    Measured: At Day 5

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2026
  2. Study start23 May 2016
  3. Primary completion30 Aug 2019
  4. Study completion4 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Crossover
Model description
Participants receive five alternative interventions during the period of the study
Masking
None (open label)
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07591961
Sponsor's protocol ID
15/HSMC/005
Other IDs
U01CA179531
Status last verified
Feb 2020
First submitted
12 Feb 2020
Last updated
18 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Food in people with Inflammation Gastrointestinal Tract, run by University of Aberdeen.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gut Microbial Metabolites (time frame: At Day 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in